Burnett Patrick's Form 4 filing
Arcutis Biotherapeutics, Inc. (ARQT) · filed Mar 4, 2025
- Accession no.
- 0001787306-25-000043
- Filed
- Mar 4, 2025
- Trade date
- Feb 28-Mar 4, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $49.4K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Burnett PatrickCIK 0001741987 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 28, 2025 | Common Stock | AGrant or awardAcquired | +38,000 | $0.00 | $0 | 152,862 | Direct | |
| Feb 28, 2025 | Common Stock | AGrant or awardAcquired | +17,000 | $0.00 | $0 | 169,862 | Direct | |
| Mar 3, 2025 | Common Stock | SSaleDisposed | −2,819 | $13.03F3 | −$36,731.57 | 167,043 | Direct | |
| Mar 4, 2025 | Common Stock | SSaleDisposed | −954 | $13.28F5 | −$12,669.12 | 166,089 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 28, 2025 | Common Stock | AGrant or awardAcquired | +99,000 | $0.00 | $0 | 99,000 | Direct | |
| Feb 28, 2025 | Common Stock | AGrant or awardAcquired | +43,000 | $0.00 | $0 | 43,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $12.6902 to $13.83, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $12.28 to $13.99, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
Remarks
Reporting Person's title: Executive Vice President, Chief Medical Officer